公开(公告)号：US20230227540A1

公开(公告)日：2023-07-20

申请号：US16475853

申请日：2018-01-05

Applicant: ABL Bio Inc.

Inventor： Jinhyung AHN ,  Sungwon AN ,  Dongin KIM ,  Eunsil SUNG ,  Jaehyun EOM ,  Sang Hoon LEE ,  Seung-Jae LEE ,  Tae Kyung KIM ,  Min Sun CHOI ,  Weonkyoo YOU ,  Jaeho JUNG ,  Juhee KIM ,  Jinwon JUNG ,  Yeunju KIM ,  Yonggyu SON ,  Byungje SUNG

IPC: C07K16/18 ,  A61P25/14 ,  G01N33/68

CPC classification number: C07K16/18 ,  A61P25/14 ,  G01N33/6896 ,  A61K2039/505 ,  C07K2317/565

Abstract: The disclosure discloses anti α-Syn antibodies preferentially recognizing α-Syn aggregates. The antibodies of the present invention bind to α-Syn aggregates with high affinity and specificity and inhibit accumulation or intercellular transfer of α-Syn aggregates, and thus can be used for detection, diagnosis and/or treatment or prevention of various diseases caused by the accumulation of α-Syn aggregates.

公开(公告)号：US20230212217A1

公开(公告)日：2023-07-06

申请号：US17789163

申请日：2020-12-24

Applicant: ABL BIO INC.

Inventor： Daehae Song ,  Youngdon Pak ,  Jinwon Jung ,  Junghyeon Hong ,  Heejin Lim ,  Dongin Kim

IPC: C07K1/22

CPC classification number: C07K1/22

Abstract: Provided is a method of purifying a mixture of Fc-containing bioactive peptides by using an affinity column including an affinity matrix containing a protein A ligand, wherein the mixture of Fc-containing bioactive peptides includes a first Fc-containing bioactive peptide and a second Fc-containing bioactive peptide, and the second Fc-containing bioactive peptide includes at least one more human VH3 domain, compared to the first Fc-containing bioactive peptide. According to the purification method, bioactive peptides having the same or similar structures can be precisely separated to the high level of purity while simplification of the process is achieved.

公开(公告)号：US20210024638A1

公开(公告)日：2021-01-28

申请号：US16939472

申请日：2020-07-27

Applicant: ABL Bio Inc. ,  YUHAN CORPORATION

Inventor： Yeryoung Yong ,  Ui-Jung Jung ,  Hyejin Chung ,  Kyeongsu Park ,  Wonjun Son ,  Yangsoon Lee ,  Yeunju Kim ,  Eunsil Sung ,  Youngkwang Kim ,  Youngdon Pak ,  Minji Park ,  Jaehyun Eom ,  Hyoju Choi ,  Moo Young Song ,  Na Rae Lee ,  Young Bong Park ,  Eun-Jung Lee ,  Eun-Jung Lee

IPC: C07K16/28 ,  A61P35/00

Abstract: Provided are an anti-4-1BB/anti-EGFR bispecific antibody, and a pharmaceutical composition and a method for treating and/or preventing a cancer using the same.

公开(公告)号：US12252541B2

公开(公告)日：2025-03-18

申请号：US17053256

申请日：2019-06-26

Applicant: ABL BIO INC.

Inventor： Kyungjin Park ,  Hyejin Chung ,  Kyeongsu Park ,  Yangsoon Lee ,  Mikyung Chang ,  Jaehyoung Jeon ,  Youngkwang Kim ,  Junhyun Jeong ,  Jiseon Yoo ,  Yeunju Kim ,  Donghoon Yeom ,  Eunjung Kim ,  Bora Lee ,  Jinwon Jung

IPC: A61K39/395 ,  A61K47/68 ,  A61P35/00 ,  C07K16/28 ,  C07K16/30 ,  A61K39/00 ,  C07K14/705

Abstract: Provided are an antibody or antigen-binding fragment thereof that specifically binds to a B-cell maturation antigen (BCMA), a method of preparing the same, and use thereof. Accordingly, these can be utilized in effectively preventing or treating cancers.

公开(公告)号：US12173070B2

公开(公告)日：2024-12-24

申请号：US17269784

申请日：2019-08-21

Applicant: ABL BIO INC.

Inventor： Eunyoung Park ,  Yangsoon Lee ,  Uijung Jung ,  YoungKwang Kim ,  Yeun Ju Kim ,  Youngdon Pak ,  Sang Hoon Lee ,  Weon-Kyoo You ,  Jaeho Jung ,  Lei Fang ,  Wenqing Jiang

IPC: C07K16/28 ,  A61K39/00 ,  A61P35/00

Abstract: The present disclosure provides an anti-PD-L1/anti-LAG3 bispecific antibody capable to effectively block the interactions between PD-L1 and its receptor PD-1 and between LAG3 and its ligand (e.g., a MHC class II molecule and FGL1). The bispecific antibody may have high binding affinity to both of a PD-L1 protein (e.g., a human PD-L1 protein) and a LAG3 protein (e.g., a human LAG3 protein). Also provided are antibodies and fragments that have specificity to the PD-L1 or LAG3 protein alone, or antibodies and fragments having additional specificity to one or more other antigens.

公开(公告)号：US20240383983A1

公开(公告)日：2024-11-21

申请号：US18684660

申请日：2021-08-18

Applicant: ABL BIO, INC.

Inventor： Kyungjin PARK ,  Yangsoon LEE ,  Saeyi LIM ,  Kyeongsu PARK ,  Minkyu SEON ,  Wonjun SON ,  Hyejin CHUNG ,  Yeryoung YONG ,  Yong-Gyu SON ,  Yeunju KIM ,  Youngdon PAK

IPC: C07K16/28 ,  A61K39/00 ,  A61P35/00

Abstract: The present disclosure provides an anti-B7-H4/anti-4-1BB bispecific antibody capable to effectively block the T-cell inhibitory effect of B7-H4 on the surface of tumor cells, and simultaneously activate 4-1BB on T-cells. The bispecific antibody may have high binding affinity to both of a B7-H4 protein (e.g., a human, monkey and mouse B7-H4 protein) and a 4-1BB protein (e.g., a human, monkey and mouse 4-1BB protein). The present disclosure also provides an anti-B7-H4 antibody specifically binds to B7-H4 protein.

公开(公告)号：US12122830B1

公开(公告)日：2024-10-22

申请号：US17057646

申请日：2019-05-23

Applicant: ABL Bio Inc.

Inventor： Yangsoon Lee ,  Juhee Kim ,  Kyungjin Park ,  Donghoon Yeom ,  Kyeongsu Park ,  Hyejin Chung ,  Yeunju Kim ,  Eunyoung Park ,  Ui-Jung Jung ,  Eunsil Sung ,  Jinhyung Ahn ,  Byungje Sung ,  Daehae Song ,  Youngdon Pak

IPC: C07K16/28 ,  A61K39/00 ,  A61P35/00 ,  G01N33/574

CPC classification number: C07K16/2803 ,  A61P35/00 ,  G01N33/57492 ,  A61K2039/505 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/92 ,  G01N2333/705 ,  G01N2333/912

Abstract: The present invention discloses an anti-ROR1 antibody specifically recognizing human and mouse ROR1. The monoclonal antibody can be usefully used for cancer targeting treatment including detection of various cancer expressing ROR1 through specific binding, and drug delivery to specific cancer, etc. as well as a cancer therapeutic agent, by inhibiting tumors.

公开(公告)号：US11891445B1

公开(公告)日：2024-02-06

申请号：US17057643

申请日：2019-05-24

Applicant: ABL Bio Inc.

Inventor： Kyeongsu Park ,  Yangsoon Lee ,  Hyejin Chung ,  Uijung Jung ,  Yong-Gyu Son ,  Sang-Jun Ha ,  Myeong Joon Kim ,  Eunyoung Park ,  Kyungjin Park ,  Eunsil Sung ,  Yeunju Kim ,  Jinhyung Ahn ,  Byungje Sung ,  Daehae Song ,  Youngdon Pak

IPC: C07K16/28 ,  G01N33/574 ,  A61P35/00 ,  A61K39/00

CPC classification number: C07K16/2827 ,  A61P35/00 ,  G01N33/57492 ,  A61K2039/505 ,  C07K2317/33 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/732 ,  C07K2317/76 ,  C07K2317/92 ,  G01N2333/70532

Abstract: Provided is an anti-B7-H3 antibody specifically recognizing a B7-H3, which can be usefully as a cancer therapeutic agent, as having an inhibitory activity of an immune checkpoint which induces antibody-dependent cell-mediated cytotoxicity and T cell activation inhibited by B7-H3. In particular, the antibody having the inhibitory activity of an immune checkpoint can be used in combination with other immunoantibody therapeutic agents. In addition, it can be usefully used for cancer targeting treatment including detection of various cancers expressing B7-H3 through specific binding to B7-H3, and drug delivery to specific cancer, etc.

公开(公告)号：US20230405139A1

公开(公告)日：2023-12-21

申请号：US18209299

申请日：2023-06-13

Applicant: LegoChem Biosciences, Inc. ,  ABL Bio, Inc.

Inventor： Yun-Hee Park ,  Ho Young Song ,  Hyun Min Ryu ,  Sung Min Kim ,  Ju Yuel Baek ,  Ji Hye Oh ,  Nara Han ,  Hyoung Rae Kim ,  Kyung Eun Park ,  Hyeun Joung Lee ,  Ju Young Lee ,  Dae Hyuck Kang ,  Young-Jae Yang ,  Ji-na You ,  Yong Zu Kim ,  Chang Sun Lee ,  Jeiwook Chae ,  Jinwon Jung ,  Juhee Kim ,  Bora Lee ,  Daehae Song ,  Byungje Sung ,  Donghoon Yeom ,  Jaehyun Eom ,  Youngeun Hong ,  Jinhyung Ahn ,  Yangsoon Lee ,  Kyungjin Park ,  Jiseon Yoo ,  Minji Park

IPC: A61K47/68 ,  A61P35/00 ,  C07K16/28

CPC classification number: A61K47/6849 ,  A61P35/00 ,  A61K47/6803 ,  C07K16/2803

Abstract: The present invention relates to new antibody-drug conjugates (ADCs) targeting ROR1, active metabolites of such ADCs, methods for preparation of such ADCs, uses for such ADCs in treatment and/or prevention of illnesses, and uses for such ADCs in production of drugs for treatment and/or prevention of diseases, more specifically diseases associated with over-expression of ROR1, for example cancer. More specifically, the present invention relates to an antibody-drug conjugate comprising an antibody that binds to ROR1 or an antigen-binding fragment thereof, and a pharmaceutical composition comprising the same.

公开(公告)号：US20230279085A1

公开(公告)日：2023-09-07

申请号：US16759937

申请日：2018-11-16

Applicant: ABL Bio Inc.

Inventor： Sang Hoon LEE ,  Weonkyoo YOU ,  Jinhyung AHN ,  Sungwon AN ,  Jinwon JUNG ,  Bora LEE ,  Dongin KIM ,  Byungje SUNG ,  Yonggyu SON ,  Yeunju KIM ,  Jaehyun EOM ,  Seawon AHN ,  Youngdon PAK ,  Donghoon YEOM ,  Daehae SONG

IPC: C07K16/18 ,  G01N33/68 ,  A61P25/28

CPC classification number: C07K16/18 ,  G01N33/6896 ,  A61P25/28 ,  C07K2317/565 ,  C07K2317/567 ,  G01N2800/2821 ,  G01N2800/2835

Abstract: The present invention relates to an anti-alpha-synuclein antibody preferentially recognizing alpha-synuclein aggregates and a use of detection, diagnosis, and/or treatment or prevention of various diseases caused by accumulation of alpha-synuclein aggregates, or their related symptom diseases by using the anti-alpha-synuclein antibody.